Last reviewed · How we verify
NCT07054346: LUTACT
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Phase 1 trial testing 177 Lutetium Prostate-Specific Membrane Antigen 617 in Prostate Cancer in 45 participants. Currently enrolling.
30 April 2027
Quick facts
| Lead sponsor | Thomas Hope |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 8 July 2025 |
| Primary completion | 30 April 2027 |
| Estimated completion | 30 April 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 177 Lutetium Prostate-Specific Membrane Antigen 617 — full drug profile →
- Actinium-225 Prostate-Specific Membrane Antigen 617 — full drug profile →
- Non-investigational, Prostatectomy
- Prostate Tissue Collection
- Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
- Blood Sample Collection — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Prostate Cancer (Diagnosis) — all drugs for Prostate Cancer (Diagnosis) →
- High-risk Prostate Cancer — all drugs for High-risk Prostate Cancer →
- Localized Prostate Carcinoma — all drugs for Localized Prostate Carcinoma →
Sponsor
Thomas Hope — full company profile →
Who can join
18 and older, male only, with Prostate Cancer or Prostate Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07054346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Thomas Hope trials
Trials by the same sponsor.
- NCT07052760 — Imaging of Solid Tumors Using DLL3 SPECT · EARLY_PHASE1 · not yet recruiting
- NCT06961084 — Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer · Phase 2 · recruiting
- NCT06474533 — Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm · recruiting
- NCT05180162 — Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 · Phase 1 · completed
- NCT04716725 — 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07054346 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Hope
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07054346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing